Sign in →

Epic Test Code LAB3845 Proteinase 3 Antibodies, IgG, Serum

Additional Codes

MML Code: PR3

LIS Code: PT3AB

NY State Approved

Yes

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Reporting Name

Proteinase 3 Ab (PR3), S

Method Name

Multiplex Flow Immunoassay

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 21 days
  Frozen  21 days


Additional Testing Requirements


To distinguish between granulomatosis with polyangiitis and other forms of anti-neutrophil cytoplasmic antibody-associated vasculitis, also order MPO / Myeloperoxidase Antibodies, IgG, Serum and ANCA / Cytoplasmic Neutrophil Antibodies, Serum; alternatively, VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum may be ordered instead, which initially tests for MPO and proteinase 3 antibodies, with reflex to ANCA when appropriate.



Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Type

Serum

Specimen Minimum Volume

0.35 mL

Reference Values

<0.4 U (negative)

0.4-0.9 U (equivocal)

≥1.0 U (positive)

Reference values apply to all ages.

Report Available

2 to 3 days

Day(s) Performed

Monday through Saturday

CPT Code Information

83516

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus OK

Useful For

Evaluating patients with clinical features of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, specifically granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis

 

Distinguishing between GPA and other forms of ANCA-associated vasculitis, in conjunction with myeloperoxidase antibody and cytoplasmic neutrophil antibody testing

 

Following treatment response or monitoring disease activity in patients with proteinase 3 antibodies

Clinical Information

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are characterized by a pauci-immune inflammation within the walls of small blood vessels.(1) There are 3 specific diseases which are identified as ANCA-associated vasculitides: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The serological hallmark of these disorders is the presence of ANCA, which are antibodies that bind to cytoplasmic antigens found in the granules of neutrophils.(2) Patients with GPA frequently have antibodies specific for proteinase 3 (PR3), while individuals with MPA or EGPA are more likely to have antibodies that bind to myeloperoxidase (MPO). The presence of PR3-ANCA and MPO-ANCA can be detected using antigen-specific immunoassays or indirect immunofluorescence (IIF). IIF is typically performed using ethanol-fixed neutrophils. Using this substrate, anti-PR3 antibodies produce a granular cytoplasmic staining pattern, which is referred to as cANCA. In comparison, due to an artefact that is a result of the fixation process, anti-MPO antibodies display a perinuclear pattern (pANCA).

 

Patients with suspected ANCA-associated vasculitis should be evaluated for the presence of PR3-ANCA, MPO-ANCA and ANCA by IIF. A consensus guideline published in 2017 recommends that patients with possible GPA or MPA be tested for PR3-ANCA and MPO-ANCA using antigen-specific immunoassays.(3) ANCA by IIF should then be used in cases where there is a high degree of suspicion for GPA or MPA, but the PR3-ANCA and MPO-ANCA testing is negative. To improve specificity of the testing, this guideline also suggests that ANCA be used in situations where a low-positive PR3-ANCA or MPO-ANCA level is detected. The classification criteria for MPA, GPA, and EGPA published by the American College of Rheumatology and the European Alliance of Associations for Rheumatology include PR3-ANCA and MPO-ANCA detected by either antigen-specific immunoassay or IIF.(4-6) These classification criteria incorporate serological ANCA testing along with clinical symptoms, imaging, and biopsy results to determine a score that allows for the classification of the various ANCA-associated vasculitides.

Interpretation

Positive results for proteinase 3 (PR3) anti-neutrophil cytoplasmic antibodies (ANCA) by antigen-specific immunoassay and cytoplasmic ANCA by indirect immunofluorescence are consistent with the diagnosis of granulomatosis with polyangiitis (GPA), in patients with the appropriate clinical presentation.

 

The reactivity of PR3-ANCA may decline with treatment of patients with GPA.

Cautions

A positive result for proteinase 3 (PR3)-anti-neutrophil cytoplasmic antibodies (ANCA), myeloperoxidase (MPO)-ANCA, or ANCA by indirect immunofluorescence is not diagnostic for any ANCA-associated vasculitis and must be interpreted in the clinical context of the patient.

 

Negative results for PR3-ANCA, MPO ANCA, and ANCA by IIF do not exclude the possibility of ANCA-associated vasculitis.

 

Monitoring reactivity of PR3-ANCA or MPO-ANCA should not be relied upon exclusively to evaluate response to treatment or to assess for risk of disease flare.

Specimen Retention Time

14 days

Forms

If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.